Goldman Sachs’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-6,701
| Closed | -$31K | – | 4357 |
|
|
2018
Q3 | $31K | Buy |
6,701
+5
| +0.1% | +$23 | ﹤0.01% | 4054 |
|
|
2018
Q2 | $31K | Buy |
6,696
+9
| +0.1% | +$42 | ﹤0.01% | 4098 |
|
|
2018
Q1 | $48K | Buy |
6,687
+11
| +0.2% | +$79 | ﹤0.01% | 4086 |
|
|
2017
Q4 | $48K | Sell |
6,676
-6,427
| -49% | -$46.2K | ﹤0.01% | 4041 |
|
|
2017
Q3 | $109K | Sell |
13,103
-1,827
| -12% | -$15.2K | ﹤0.01% | 4023 |
|
|
2017
Q2 | $152K | Sell |
14,930
-2,386
| -14% | -$24.3K | ﹤0.01% | 4057 |
|
|
2017
Q1 | $200K | Sell |
17,316
-23,520
| -58% | -$272K | ﹤0.01% | 3955 |
|
|
2016
Q4 | $521K | Sell |
40,836
-10,290
| -20% | -$131K | ﹤0.01% | 3434 |
|
|
2016
Q3 | $936K | Sell |
51,126
-163,071
| -76% | -$2.99M | ﹤0.01% | 3093 |
|
|
2016
Q2 | $2.27M | Buy |
214,197
+33,700
| +19% | +$358K | ﹤0.01% | 2541 |
|
|
2016
Q1 | $3.41M | Sell |
180,497
-14,400
| -7% | -$272K | ﹤0.01% | 2268 |
|
|
2015
Q4 | $5.18M | Sell |
194,897
-3,164
| -2% | -$84.2K | ﹤0.01% | 2016 |
|
|
2015
Q3 | $9.03M | Sell |
198,061
-12,033
| -6% | -$549K | ﹤0.01% | 1678 |
|
|
2015
Q2 | $6.77M | Buy |
210,094
+49,255
| +31% | +$1.59M | ﹤0.01% | 1891 |
|
|
2015
Q1 | $5.12M | Buy |
160,839
+156,159
| +3,337% | +$4.97M | ﹤0.01% | 2020 |
|
|
2014
Q4 | $177K | Buy |
4,680
+3,678
| +367% | +$139K | ﹤0.01% | 4049 |
|
|
2014
Q3 | $26K | Sell |
1,002
-1,051
| -51% | -$27.3K | ﹤0.01% | 4436 |
|
|
2014
Q2 | $61K | Sell |
2,053
-1,831
| -47% | -$54.4K | ﹤0.01% | 4263 |
|
|
2014
Q1 | $144K | Buy |
3,884
+575
| +17% | +$21.3K | ﹤0.01% | 4055 |
|
|
2013
Q4 | $137K | Buy |
3,309
+975
| +42% | +$40.4K | ﹤0.01% | 4018 |
|
|
2013
Q3 | $124K | Sell |
2,334
-2,080
| -47% | -$111K | ﹤0.01% | 3978 |
|
|
2013
Q2 | $236K | Buy |
+4,414
| New | +$236K | ﹤0.01% | 3552 |
|